- Home
- NEGG vs CYCC Comparison
NEGG vs CYCC Comparison
Compare NEGG & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- CYCC
- Stock Information
- Founded
- NEGG 2001
- CYCC 1992
- Country
- NEGG United States
- CYCC Malaysia
- Employees
- NEGG N/A
- CYCC N/A
- Industry
- NEGG Other Specialty Stores
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- CYCC Health Care
- Exchange
- NEGG Nasdaq
- CYCC Nasdaq
- Market Cap
- NEGG 75.6M
- CYCC 61.2M
- IPO Year
- NEGG 2010
- CYCC N/A
- Fundamental
- Price
- NEGG $5.30
- CYCC $1.66
- Analyst Decision
- NEGG
- CYCC
- Analyst Count
- NEGG 0
- CYCC 0
- Target Price
- NEGG N/A
- CYCC N/A
- AVG Volume (30 Days)
- NEGG 301.4K
- CYCC 191.0K
- Earning Date
- NEGG 04-28-2025
- CYCC 05-15-2025
- Dividend Yield
- NEGG N/A
- CYCC 147.24%
- EPS Growth
- NEGG N/A
- CYCC N/A
- EPS
- NEGG N/A
- CYCC N/A
- Revenue
- NEGG $1,235,576,000.00
- CYCC $14,000.00
- Revenue This Year
- NEGG N/A
- CYCC $137.21
- Revenue Next Year
- NEGG N/A
- CYCC N/A
- P/E Ratio
- NEGG N/A
- CYCC N/A
- Revenue Growth
- NEGG N/A
- CYCC N/A
- 52 Week Low
- NEGG $3.32
- CYCC $1.36
- 52 Week High
- NEGG $26.40
- CYCC $49.34
- Technical
- Relative Strength Index (RSI)
- NEGG 49.69
- CYCC 32.68
- Support Level
- NEGG $4.82
- CYCC $1.36
- Resistance Level
- NEGG $6.63
- CYCC $1.82
- Average True Range (ATR)
- NEGG 1.07
- CYCC 0.35
- MACD
- NEGG -0.07
- CYCC -0.04
- Stochastic Oscillator
- NEGG 14.39
- CYCC 9.73
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.